Dublin: "Miraculous" New Drug (Ibrutinib) Hailed As Breakthrough In Leukaemia Treatment

Scientists at the Royal College of Surgeons in Ireland were involved in the clinical trials of the drug

An international trial of a new drug for the treatment of the most common form of leukaemia has found it increases survival rates.

The drug leads to more sufferers being clear of the disease within one year, produces fewer side effects and is effective for those with a resistance to chemotherapy.

Scientists at the Royal College of Surgeons in Ireland were involved in the clinical trials of the drug.

RELATED AUDIO & VIDEO

• Watch: Dr Patrick Thornton, Consultant Haemotologist, discusses new leukaemia treatment

Chronic lymphocytic leukaemia is a slow-growing cancer affecting cells that fight disease in bodies.

Leukaemia claims 200 lives in Ireland annually, and CLL accounts for nearly half of the 500 new cases of the disease diagnosed in the country each year.

While conventional treatments for leukaemia are reasonably effective, they can cause severe side effects.

However, a new drug, Ibrutinib, is being hailed as a breakthrough in leukaemia treatment.

It has been trialled on 400 patients internationally, including in Ireland.

Trial results, published in the New England Journal of Medicine, showed survival rates for patients using it rose 10% when compared to the conventional treatments, and patients responded more quickly.

Those trying the drug reported fewer side effects and it was also effective on those whose cancer cells have built up resistance to chemotherapy.

Report co-author Dr Patrick Thornton from the Royal College of Surgeons in Ireland said the new drug represents a complete paradigm shift in leukaemia treatment, which could replace the need for chemotherapy.

Speaking on RTÉ's Morning Ireland, Dr Thornton said: "It works for all CLL, but in particular it works for the most risky version of CLL - people with various chromosomal deletions that normally do very badly or are resistant to chemotherapy, and have a very shortened survival.

"This drug seems to overcome that resistance and is extremely effective with very little side effects."

The consultant haematologist at Beaumont Hospital described the effects of the new drug on some patients as "nothing short of miraculous".

He said Ibrutinib can be given in tablet form to replace the more severe and invasive chemotherapy.

Keywords: leukaemia, ibrutinib